Due to the effectiveness of SGLT2 inhibitors in the treatment of heart failure and their pleiotropic mechanism of action, there are increasing attempts to use this group of drugs in other cardiovascular diseases. The gene discussed is SLC5A2; the disease is cardiovascular disorder.